Executive Summary:
This document pertains to the recruitment process for filling vacant posts at the Central Drugs Testing Laboratory (CDTL) in Chennai. It references an earlier office memorandum and addresses the scrutiny of applications received. The document outlines the next steps in the recruitment process, culminating in the finalization of appointments by 31.03.2019.
Key Points / Main Content:
* **Reference:** The document refers to Office Memorandum No. CDTL/528/Rectt./Actt./2018-19/1718 dated 29.01.2018.
* **Application Review:** Applications received in response to the earlier notification were scrutinized, and observations regarding deficiencies or incomplete information were communicated to candidates.
* **Recruitment Process Continuation:** After due consideration, the Director has approved further processing of the recruitment for vacant posts at CDTL, Chennai.
* **Finalization Date:** The target date for completing the appointment process is 31.03.2019.
Impact Analysis:
Director Admn., Central Drugs Standard Control Organisation:
* Impact: Required to note the update regarding the recruitment process at CDTL Chennai.
* Action Required: No specific action is mentioned other than noting the information.
Key Entities Referenced
Central Drugs Standard Control Organisation: A regulatory body in India responsible for drug regulation.
Central Drugs Testing Laboratory: A drug testing laboratory, NABL accredited, under the Central Drugs Standard Control Organisation.
NABL: An accreditation body, likely referring to the National Accreditation Board for Testing and Calibration Laboratories.
FDA Bhavan, Kotla Road, New Delhi 110 002: Address of the Central Drugs Standard Control Organisation.
New Delhi: Capital of India.
CDTL528Rectt.Actt.201819: Reference number for the recruitment related action.
G.M.S.D CAMPUS, NO.37, NAVAL HOSPITAL ROAD, Chennai, Tamil Nadu: Address of the Central Drugs Testing Laboratory
Director Admn., Central Drugs Standard Control Organisation: Designation of the recipient of the notification.
HIRT ACHIT
oaF ra —r ee ar -ey a a re va ef ra t er e rB err za y y Faery, : DTEM ./ o G. EH NE EA RLG ATO LH V O&E F R F HAN EMM AI LE L TN Y HT W S O E EF L RV FI IAN CD R EI E SA aise af ca tee r sA aa rra er U reT rrS CENTRAL DRUGS STANDARD CONTROL ORGANISATION
UTA Wears WANT ereaT CENTRAL DRUGS TESTING LABORATORY
ofa NABL ACCREDITATED LABORATORY aaaew ,e =d rt a. -a 6r 0r 0e ,
0
03 3.37, Fae areca a,
G.M.S.D CAMPUS, NO.37, NAVAL HOSPITAL ROAD
Tel.Ph. :0 44-25610402, E-mail - cdtlchennai@cdsco.nic..in, TelP e.E FR aI xA :M 0E 44T -,
2
5C 6H 1E 0N 9N 0A 6I-600003.
No.CDTL/528/Rectt.Actt./2018-19/
ane
dated the 28th January, 2019
To
?
The Director Admn.,
Central Drugs Standard Control Organisation,
Dte. General of Health Services,
FDA Bhavan, Kotla Road,
New Delhi-1 10 002.
Sub:- rCA G eed r cnv o ete u irr pp at tl i ‘ os C D f’e r Am u pNe g pon s lnt
i
- T cg G aei a tsv z ite e oin nnt sgti n e
-
L dt a Rh b ee p o
g
o rC .s atD t oS o rfC y ,AO c C cW hoe eub nns nti aat ine t — r oe Rng e a qdr ued epi sun tg ta f tti oil l o ei nn xg tbu eap ns dio sf
t
ho i enn e t
la
hv se ta c o dfa afn tit ece foo rf
Ref.:-1 2. . D Tt he i. s’s o fO ff if ci ec e l eM tte em r o Nor .a Cn Dd TLu /m 5 2N 8o /. RA e- c1 t2 t0 .1 A8 c/ t0 t1 ./ 22 00 171 -8 1- 8D
/
d 3a 1t 4e 2d
d
2 a9 t. e0 d1 . 12 50 .1 08 2.
.2018.
WfaobwDMRaSC ri nnyi eu ecu lD or d llp c t bmtT e d ee o hh tc sL e aisr r t aao ps l, i a kd nd u s Rn e oeW tyt ov fe n di o ai efC tcu of t td ii fih ra b nh ie c fR r e ut y e o ie e tin ir c nc f ihto te Dn r o at eh mf n ta br lou ee e s / i ai Eg or n’ f st iDo fie mt le ir flf i vn s p n ii r ic f cs u e le na ee t O n ap gc i o h f t l n t tvt ye if i ato ldo a f i n lmh dr o g cc ea e dva ri e na a tb e nwn en t tpeo rh tc oh ect tv M i s u t e . eie tcee Nm s. s, p hb ew m sf e Io ii t te waoli m s ht blt n s ir er t rh y si t u .yno s a op u t tdn ft g ha e eoo ht eif d d Bpf A n.h rf uv uu i c ee etettn cc m t D f,h raf t v o ih o eo tt re a ru t r i ie ec hnN Cm f o c s i a to p tnr s reDn at o . o emth s n SRA oim qea t ft en. C unpt . fc c1 t eo ia Ol ro 0 2 c ss s u u e1n 0 w t td i . We 4 ep aiN t1 heo 8 n dee sm f abp g1 / r c e s o s t . A 0 ne g os D s i2 c 1 t s irt h nt0 c ,/ kvs a o oe1 io 2o ef ra t n 7 Df u 0 t nt r f di n 1 - oA ry lR rt t r8 i e yc ed e n ea - cc c rcu rp un D eto e tr me e pt i o c hu u r lv r r en i cdm a oea u ot tt i as at din Ca mo s et d tt en s p De r amn wt i e iad e nSr nt c ro a n y es t n Cts tt ”a RR 2 hi . aCn ue t9 e r pr ohc lc . e p et a e0r CWtS lm qi ss 1u ehi ie Duo . i cenn ben i2t Sa ct ssb se p t0 em i Cted o i“1 ,e te o se B8 Oo n e nt d t.n y in t to vacant pot so t t oh f e e Af cf ce cc ot u t nh ta at n tt h ate Cla Ds Tt L d ,a t Ce h ef nor n ar iec oei np t d eo pf u ta ap tp ili oc na t bi ao sn is s f ao sr 3r 1e .c 0r 3u .i 2t 0m 1e 9n .t fo the
—
wadhr,
Yours faithfully,
Pi
ST Gray
PR OF ag ve
(DCN. MUBtR AUr.G E SWaAilNeaT)
(0 yk )% PH.fNiOd.e0r4e4n-/2D5I6R1E0C9T0O6R
\ yl
6
ae;
gn = ober allie faa ste> w/ hDi er mec t qa ar
ngrey
-entral Drugs Testing Laboratory
MRA ares / Government
of India
Be epee